Life Science

This mixture contains each of the (S)-monohydroxy lipoxygenase products of arachidonic acid. Contents: 5(S)-HETE, 8(S)-HETE, 11(S)-HETE, 12(S)-HETE, and 15(S)-HETE (5 &microg each).

An enantiomer of ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form also inhibits activation of NF-&kappaB more effectively than (R)-ibuprofen (IC₅₀s = 62 and 122

An enantiomer of ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form also inhibits activation of NF-&kappaB more effectively than (R)-ibuprofen (IC₅₀s = 62 and 122

An enantiomer of ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form also inhibits activation of NF-&kappaB more effectively than (R)-ibuprofen (IC₅₀s = 62 and 122

An enantiomer of ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form also inhibits activation of NF-&kappaB more effectively than (R)-ibuprofen (IC₅₀s = 62 and 122

A potent inhibitor of COX-1 and COX-2 (IC₅₀s = 1.9 and 27 nM, respectively), whereas the (R)-enantiomer is 100 to 1,000 times less potent.

A potent inhibitor of COX-1 and COX-2 (IC₅₀s = 1.9 and 27 nM, respectively), whereas the (R)-enantiomer is 100 to 1,000 times less potent.

A potent inhibitor of COX-1 and COX-2 (IC₅₀s = 1.9 and 27 nM, respectively), whereas the (R)-enantiomer is 100 to 1,000 times less potent.

A potent inhibitor of COX-1 and COX-2 (IC₅₀s = 1.9 and 27 nM, respectively), whereas the (R)-enantiomer is 100 to 1,000 times less potent.

The pharmacologically inactive optical enentiomer of (R)-LSF.

The pharmacologically inactive optical enentiomer of (R)-LSF.

The pharmacologically inactive optical enentiomer of (R)-LSF.